Total Payments
$15,340
2024 Payments
$13,002
Companies
18
Transactions
42
Medicare Patients
1,290
Medicare Billing
$209,895
Payment Breakdown by Category
Consulting$9,600 (62.6%)
Research$2,944 (19.2%)
Food & Beverage$2,036 (13.3%)
Travel$759.17 (4.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,600 | 1 | 62.6% |
| Unspecified | $2,944 | 3 | 19.2% |
| Food and Beverage | $2,036 | 35 | 13.3% |
| Travel and Lodging | $759.17 | 3 | 4.9% |
Payments by Type
General
$12,395
39 transactions
Research
$2,944
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ADC Therapeutics America, Inc. | $10,938 | 11 | $0 (2024) |
| F. Hoffmann-La Roche AG | $2,944 | 3 | $0 (2024) |
| Adaptive Biotechnologies Corporation | $338.10 | 3 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $232.30 | 2 | $0 (2019) |
| Genentech, Inc. | $156.46 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $152.61 | 8 | $0 (2019) |
| Seagen Inc. | $116.96 | 1 | $0 (2023) |
| Genentech USA, Inc. | $99.79 | 1 | $0 (2023) |
| Celgene Corporation | $64.29 | 1 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $48.63 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,002 | 14 | ADC Therapeutics America, Inc. ($10,938) |
| 2023 | $1,442 | 7 | F. Hoffmann-La Roche AG ($921.81) |
| 2022 | $325.37 | 4 | Adaptive Biotechnologies Corporation ($191.62) |
| 2019 | $454.26 | 16 | Novartis Pharmaceuticals Corporation ($152.61) |
| 2018 | $116.91 | 1 | AstraZeneca Pharmaceuticals LP ($116.91) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,357.77 | Research |
| Study: MorningSun | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $664.77 | Research |
| Study: MorningSun | ||||||
| 12/18/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $64.27 | General |
| 12/10/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $110.00 | General |
| 12/10/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $104.28 | General |
| 10/31/2024 | ADC Therapeutics America, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,600.00 | General |
| 09/20/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $322.94 | General |
| 09/20/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $140.00 | General |
| 09/20/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $100.00 | General |
| 09/20/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $72.00 | General |
| 09/20/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $40.00 | General |
| 09/06/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $331.95 | General |
| 08/20/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $52.91 | General |
| 01/20/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $40.68 | General |
| Category: ONCOLOGY | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $921.81 | Research |
| Study: MorningSun | ||||||
| 12/11/2023 | Genentech, Inc. | Lunsumio (Biological) | Food and Beverage | In-kind items and services | $87.00 | General |
| Category: BioOncology | ||||||
| 12/11/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: Oncology | ||||||
| 12/10/2023 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $99.79 | General |
| 12/10/2023 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $47.21 | General |
| Category: Monoclonal Antibody | ||||||
| 12/08/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $146.48 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2023 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $116.96 | General |
| 12/11/2022 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $69.46 | General |
| 12/10/2022 | Adaptive Biotechnologies Corporation | — | Food and Beverage | In-kind items and services | $156.24 | General |
| 12/09/2022 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $64.29 | General |
| 10/12/2022 | Adaptive Biotechnologies Corporation | — | Food and Beverage | In-kind items and services | $35.38 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MorningSun | F. Hoffmann-La Roche AG | $2,944 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 399 | 700 | $160,450 | $64,814 |
| 2022 | 9 | 477 | 841 | $176,701 | $75,483 |
| 2021 | 8 | 363 | 722 | $141,433 | $62,029 |
| 2020 | 3 | 51 | 65 | $18,748 | $7,568 |
Total Patients
1,290
Total Services
2,328
Medicare Billing
$209,895
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 140 | 314 | $64,347 | $31,743 | 49.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 111 | $29,969 | $10,088 | 33.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 95 | 140 | $26,166 | $9,569 | 36.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $14,419 | $5,371 | 37.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 23 | $9,871 | $3,047 | 30.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 45 | $7,956 | $2,718 | 34.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 23 | $7,722 | $2,279 | 29.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 116 | 306 | $51,864 | $31,786 | 61.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 99 | 161 | $25,099 | $10,902 | 43.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 65 | 137 | $33,565 | $10,471 | 31.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 45 | 47 | $22,325 | $6,958 | 31.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 52 | 87 | $14,790 | $4,658 | 31.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 34 | 34 | $10,452 | $4,592 | 43.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 27 | 30 | $10,500 | $3,077 | 29.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $6,528 | $2,477 | 37.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 12 | $1,578 | $562.77 | 35.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 83 | 205 | $34,062 | $22,505 | 66.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 98 | 189 | $29,309 | $13,559 | 46.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 55 | 145 | $24,962 | $7,970 | 31.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 38 | 91 | $22,695 | $7,100 | 31.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 33 | 33 | $9,963 | $4,570 | 45.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 19 | $9,281 | $2,929 | 31.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 27 | 28 | $9,613 | $2,820 | 29.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 11 | 12 | $1,548 | $575.08 | 37.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 19 | 20 | $9,820 | $3,140 | 32.0% |
About Dr. Aung Tun, M.D
Dr. Aung Tun, M.D is a Hematology healthcare provider based in Westwood, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2015. The National Provider Identifier (NPI) number assigned to this provider is 1033508304.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aung Tun, M.D has received a total of $15,340 in payments from pharmaceutical and medical device companies, with $13,002 received in 2024. These payments were reported across 42 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($9,600).
As a Medicare-enrolled provider, Tun has provided services to 1,290 Medicare beneficiaries, totaling 2,328 services with total Medicare billing of $209,895. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Medical Oncology
- Location Westwood, KS
- Active Since 01/09/2015
- Last Updated 08/28/2025
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1033508304
Products in Payments
- clonoSEQ (Device) $146.48
- LYNPARZA (Drug) $116.91
- TAGRISSO (Drug) $115.39
- Lunsumio (Biological) $87.00
- PROMACTA (Drug) $62.47
- ULTOMIRIS (Drug) $48.63
- Poteligeo (Drug) $47.21
- NINLARO (Drug) $41.43
- EPKINLY (Drug) $40.68
- PIQRAY (Drug) $33.42
- Nerlynx (Drug) $30.87
- PROVENGE (Drug) $29.12
- Epkinly (Drug) $22.32
- Lonsurf (Drug) $21.57
- SANDOSTATIN (Drug) $16.78
- KEYTRUDA (Biological) $14.64
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.